Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been assigned a consensus rating of “Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $187.33.
A number of equities analysts recently issued reports on the company. BidaskClub raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. Piper Jaffray Companies initiated coverage on IDEXX Laboratories in a report on Tuesday, January 16th. They set an “overweight” rating and a $200.00 price target on the stock. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th.
In related news, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jonathan W. Ayers sold 2,160 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the sale, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at approximately $179,910,017.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,160 shares of company stock valued at $20,019,685. 2.77% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of IDEXX Laboratories by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock valued at $1,495,488,000 after acquiring an additional 354,024 shares during the period. BlackRock Inc. lifted its position in shares of IDEXX Laboratories by 10.5% during the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares during the period. Koch Industries Inc. lifted its position in shares of IDEXX Laboratories by 44,533.1% during the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares during the period. Renaissance Technologies LLC lifted its position in shares of IDEXX Laboratories by 38.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after acquiring an additional 376,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of IDEXX Laboratories by 42.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares during the period. Hedge funds and other institutional investors own 86.66% of the company’s stock.
IDEXX Laboratories (NASDAQ:IDXX) traded up $1.63 during midday trading on Tuesday, hitting $180.63. The company had a trading volume of 587,046 shares, compared to its average volume of 383,870. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. IDEXX Laboratories has a 52-week low of $116.54 and a 52-week high of $180.88. The stock has a market capitalization of $15,754.37, a price-to-earnings ratio of 58.46, a P/E/G ratio of 2.43 and a beta of 0.42.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. During the same quarter last year, the company posted $0.62 earnings per share. The business’s revenue was up 9.7% on a year-over-year basis. equities analysts forecast that IDEXX Laboratories will post 3.24 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Analysts Set IDEXX Laboratories, Inc. (IDXX) Price Target at $187.33” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/analysts-set-idexx-laboratories-inc-idxx-price-target-at-187-33.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.